Company intelligence / Profile preview

Alzohis

Paris, Île-de-France, Francealzohis.com ↗

Ownership: Private
Development stage: Other

Overview

Alzohis has developed Noratest®, the first non-invasive blood-based diagnostic test for Alzheimer’s disease available in Europe. The test uses a proprietary algorithm that correlates plasma catecholamine levels with MMSE cognitive scores, age, and sex to provide an early diagnosis of Alzheimer’s. Noratest® is commercially available in many laboratories across France and provides results within 1–2 months after testing

Therapeutic areas: Neurology
Modalities: Diagnostic testDevice (in vitro diagnostic blood test)
Industry: Metabolite Diagnostics

Partnerships

European Union Horizon 2020 research program funding partner

Beyond the preview

Go deeper on Alzohis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzohis.

Explore the full profile